Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial (NCT02730208) enrolled 41 people with cystic fibrosis — 20 received a combination medicine called TEZ/IVA (tezacaftor/ivacaftor) and 21 received a placebo (a dummy treatment with no active ingredient). All 20 people in the TEZ/IVA group completed the study, while 20 out of 21 in the placebo group completed it. The main thing the trial was measuring was change in a lung CT scan score called the Brody/CF-CT score, which rates the visible structural damage to the lungs on a scale from 0 to 219 — a higher number means more damage is visible on the scan. The reported data shows that, on average, the Brody/CF-CT score changed by 0.90 points in the TEZ/IVA group and by 2.38 points in the placebo group over the course of the study. Both figures represent small increases from baseline (meaning slightly higher scores, suggesting slightly more visible lung changes on the scan), though the numbers reported are the average changes and no further breakdown was provided in the submitted data. As a secondary measure, the trial also recorded how many participants experienced adverse events (unexpected health problems during the study) and serious adverse events. The reported data shows that all 20 participants in the TEZ/IVA group and all 21 in the placebo group had at least one adverse event reported, while serious adverse events were reported in 8 participants in the TEZ/IVA group and 13 in the placebo group. It is important to note that these numbers alone do not tell us whether any differences between the groups are meaningful, and no conclusions about whether the treatment works or is safe can be drawn from these figures alone. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 2 Cystic Fibrosis Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You must have cystic fibrosis (CF) caused by having two copies of a specific gene change called "F508del" (one inherited from each parent)
- You must have an official diagnosis of cystic fibrosis
- Your lung function test results (measuring how much air you can breathe out forcefully) must be at or above 70% of what is considered normal for your age, sex, and height
- Your CF must be considered stable and well-controlled, as judged by the study doctor
Who may not be able to join:
- You may not be eligible if you have other health conditions that the study doctor believes could affect the study results or make the study medication risky for you
- You may not be eligible if you have had a recent lung or breathing infection, a CF flare-up, or any changes to your lung treatments (including antibiotics) in the 28 days before starting the study
- Women who are pregnant or currently breastfeeding cannot join
- Sexually active participants who are able to have children but are not willing to use an approved method of contraception during the study cannot join
- You may not be eligible if there is any medical reason why you cannot have chest imaging (scans), based on the rules at the study site (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
9 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Absolute Change in Total Brody/CF-CT Score
Can't join this trial?
Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.